PrEP

Ava Avalos, MD, details the effects of a dolutegravir-based regimen on pregnancy.

Young MSM who saw PrEP4Love ads were nearly 3 times as likely to have spoken with a care provider about PrEP than those unaware of the campaign.

There currently aren’t any clear guidelines for how health care providers should handle discrepant—1 positive and 1 negative—HIV test results during pregnancy.

A study of MSM suggests optimizing at-home testing for STIs and HIV could increase rates of testing, while noting a need to balance convenience with educational outreach.

Paul Drain, MD, MPH, explains how point-of-care viral load testing was successful in providing rapid results to patients in a South African-based study.

A new CDC report suggests that 80% of new HIV cases were transmitted by individuals who were unaware they had HIV or who were not receiving consistent care.

The makers of leronlimab (PRO 140) have filed the non-clinical portion of the drug’s Biologics License Application as a combination therapy for HIV with the FDA.

A communitywide HIV prevention package including in-home testing and antiretroviral therapy reduces new infections, according to a study from the HIV Prevention Trials Network.

A study presented at CROI 2019 found that interventions to support PrEP persistence for younger black MSM will be necessary in order for the full effectiveness of PrEP to be achieved.

On-demand pre-exposure prophylaxis with TDF/FTC is not associated with a clinically relevant change in kidney function the way daily PrEP use is, investigators in France found.

CROI 2019 was held March 4-7, 2018, in Seattle, Washington. The conference featured results of new studies on a variety of HIV topics as well as advancements being made in the field. Here are 5 key takeaways from the meeting.

Kavita Misra, PhD, MPH, explains how health care providers can help prevent PrEP resistance from growing by increasing screening for acute HIV infection.

Julia Marcus, PhD, MPH, discusses the barriers of PrEP use and how current prescribing guidelines are used in clinical practice.

Paul Sax, MD, details his research on integrase inhibitor-based regimens and weight gain.

From the London Patient to the DISCOVER trial and everything in between, HIV experts provide their biggest takeaways from CROI 2019, in the second part of our highlight reel.

Brad Hare, MD, explains how the findings of the DISCOVER study indicate that PrEP is no longer a one-size-fits-all situation.

From the London Patient to the DISCOVER trial and everything in between, HIV experts provide their biggest takeaways from CROI 2019.

Bluma Brenner, PhD, confesses that HIV "terrifies the hell" out of her, as it continues to build resistance against existing therapy regimens.

Kristine Erlandson, MD, MS, shares her findings on the connection between obesity and neurocognitive decline in persons with HIV.

Short-term investments in pre-exposure prophylaxis (PrEP) are predicted to result in long-term cost-savings and promote significant health benefits following its distribution in Germany, according to a new modelling study in Eurosurveillance.

Laura Waters, MD, FRCP, an author on the Nature article on the reported HIV remission of the London Patient, explains why it is too soon to label the remission as a cure.

In a symposium at CROI 2019, Jean-Michele Molina, MD, presented on PrEP failures, highlighting elements of diagnosis, resistance and treatment.

Monica Gandhi, MD, MPH, discusses antiretroviral options and and treatment decisions for women of reproductive potential.

In a symposium at CROI 2019, Laura Waters, MD, FRCP, presented on the developments of 2-drug regimens for HIV treatments, as well as the questions that remain unanswered.

Persistence on HIV pre-exposure prophylaxis drops off dramatically over a 2-year time period, with only 2 out of 5 users persisting on the treatment, according to a recent study from Emory University.

Paul Sax, MD, shares his take on news of the second person ever achieving long-term HIV remission.

Susan Swindells, MBBS, discusses the ATLAS trial evaluating long-acting intramuscular injections of cabotegravir/rilpivrine in treatment-experienced individuals.

A new study examining tuberculosis and HIV coinfection in patients in Latin America has found that those with TB had higher mortality rates over the course of a decade, despite successful TB treatment.

Lynne Mofenson, MD, spoke to Contagion® in an exclusive interview to explain what the current data suggest on the impact of antiretroviral therapy on maternal health and pregnancy outcomes.

Pietro Vernazza, MD, discusses his presentation on the scientific underpinnings of U=U 11 years after issuing the Swiss Statement